O

OSIVAX

40 employees

Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.

Basic info

Industry

biotechnology research

Sectors

cellular immune response

Biotechnology

biotechnology

covid

CD8 T-cell

antigens

Clinical Trials

Immuno-oncology

vaccine

Health Care

Infectious diseases

Influenza

immunology

universal

Date founded

2017

Funding rounds raised

Total raised

$17M

from 5 investors over 5 rounds

O

OSIVAX raised $1M on March 28, 2023

Investors: Bill & Melinda Gates Foundation

O

OSIVAX raised $17M on July 8, 2020

Investors: Anaxago

O

OSIVAX raised $9M on July 10, 2019

Investors: Anaxago and -

O

OSIVAX raised $3M on June 15, 2017